Advances In Non-Invasive Ventilation: Explore the Latest Developments in Non-Invasive Ventilation Techniques, Such as High-Flow Na

[1]Wael Ramadan AL Anazi, [2]Abdulkarim Farhan Alanazi,[3] Mohammed Hassan Alsomali, [4]Wael Mohammed Alqahtani, [5]Mohammed salem Albalawi, [6]Mohammed Obaid alshammari, [7]Abdulaziz Alrasheed

[1,5,6]Respiratory Therapist, King Abdullah Specialized children Hospital
[2,3,4]Respiratory Therapist, National Guard Hospital, Riyadh, SA
[7] Respiratory Therapist, Ministry of National Guard Health Affairs
Corresponding Author: **Wael Ramadan AL Anazi**

Paper Publication Date: 2nd February-2021

Abstract-
Non-invasive ventilation (NIV) has revolutionized the management of respiratory failure, offering a less invasive alternative to traditional mechanical ventilation. One of the latest developments in NIV techniques is high-flow nasal cannula (HFNC) therapy, which delivers high-flow humidified oxygen to patients through nasal prongs. This essay will explore the advancements in HFNC therapy, discussing its mechanism of action, indications, advantages, and limitations. The method, results, and discussion sections will analyze recent studies on the effectiveness of HFNC therapy in various clinical settings. Ultimately, this essay aims to highlight the potential benefits of HFNC therapy in improving patient outcomes and reducing the need for invasive ventilation.

Keywords: Non-invasive ventilation, high-flow nasal cann, respiratory failure, oxygen therapy, mechanical ventilation

Published in IJIRMPS (E-ISSN: 2349-7300), Volume 9, Issue 1, Jan- Feb 2021

Introduction:

Non-invasive ventilation has gained popularity in recent years as a first-line therapy for respiratory failure, avoiding the complications associated with invasive mechanical ventilation. High-flow nasal cannula (HFNC) therapy is a relatively new form of NIV that delivers heated and humidified oxygen at high flow rates through nasal prongs. The high flow of oxygen generated by HFNC therapy washes out the upper airways, reduces dead space, and provides positive airway pressure, thereby improving oxygenation and ventilation. This essay will delve into the latest advancements in HFNC therapy, examining its role in the management of acute and chronic respiratory failure.

Non-invasive ventilation (NIV) techniques are respiratory support methods that deliver positive pressure ventilation without the need for an invasive airway device, such as an endotracheal tube or tracheostomy. NIV can be used to support patients with acute or chronic respiratory failure and can provide several benefits, including improved gas exchange, reduced work of breathing, and avoidance of complications associated with invasive mechanical ventilation. Here are some non-invasive ventilation techniques commonly used in respiratory therapy:

Continuous Positive Airway Pressure (CPAP): CPAP delivers a constant positive pressure throughout the respiratory cycle to keep the airways open. It is primarily used to treat obstructive sleep apnea but can also be beneficial in managing conditions such as acute pulmonary edema or respiratory distress associated with preterm infants.
Bilevel Positive Airway Pressure (BiPAP): BiPAP provides two levels of positive pressure: inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). IPAP is set to assist with inspiration, while EPAP maintains positive pressure during expiration. BiPAP is commonly used in conditions such as chronic obstructive pulmonary disease (COPD) exacerbations or respiratory failure due to neuromuscular disorders.
Non-Invasive Positive Pressure Ventilation (NIPPV): NIPPV is a broader term that encompasses both CPAP and BiPAP. It involves the delivery of positive pressure throughout the respiratory cycle to assist with ventilation and oxygenation. NIPPV can be used in various acute and chronic respiratory conditions, such as pneumonia, acute exacerbations of COPD, and obesity hypoventilation syndrome.
High-Flow Nasal Cannula (HFNC) Therapy: HFNC delivers heated and humidified oxygen at high flow rates through a nasal cannula. It provides oxygenation and can generate positive airway pressure, helping to improve respiratory mechanics and reduce work of breathing. HFNC is commonly used in conditions such as acute respiratory failure, post-extubation support, and bronchiolitis in pediatric patients.
Volume-Assured Pressure Support (VAPS): VAPS is a mode of non-invasive ventilation that combines the benefits of pressure support ventilation and volume targeting. It adjusts the pressure support level to achieve a targeted tidal volume, providing better synchronization with the patient's respiratory effort. VAPS can be useful in patients with respiratory muscle weakness or insufficient spontaneous ventilation.

Automatic Adjusting Positive Airway Pressure (APAP): APAP, also known as auto-titrating positive airway pressure, is primarily used in the management of obstructive sleep apnea. It automatically adjusts the pressure delivered based on the patient's airflow and respiratory patterns, ensuring optimal treatment with minimal discomfort.
The selection of the appropriate non-invasive ventilation technique depends on the patient's clinical condition, underlying respiratory pathology, and individual response to therapy. Respiratory therapists play a crucial role in assessing patients, titrating the appropriate settings, monitoring treatment effectiveness, and providing patient education and support when implementing non-invasive ventilation techniques.

Method:
A comprehensive literature review was conducted to identify recent studies on HFNC therapy in various clinical contexts. Electronic databases such as PubMed, MEDLINE, and Google Scholar were searched using keywords such as "high-flow nasal cannula," "non-invasive ventilation," and "respiratory failure." Only studies published in peer-reviewed journals within the last five years were included in this review. Relevant articles were selected based on their focus on the mechanism of action, indications, outcomes, and complications of HFNC therapy.

Results:
Recent studies have demonstrated the efficacy of HFNC therapy in improving oxygenation and respiratory parameters in patients with acute respiratory failure such as pneumonia, acute respiratory distress syndrome (), and chronic obstructive pulmonary disease (COPD). HFNC therapy has been shown to reduce the need for intubation and invasive mechanical ventilation in these patients, leading to shorter hospital stays and improved outcomes. Additionally, HFNC therapy has been used successfully in post-extubation patients to prevent reintubation and facilitate weaning from mechanical ventilation.

Discussion:
The benefits of HFNC therapy extend beyond its role in acute respiratory failure, with studies highlighting its potential in chronic respiratory conditions such as COPD and obstructive sleep apnea. HFNC therapy provides improved patient comfort, better humidification, and reduced nasal irritation compared to conventional oxygen therapy. Furthermore, HFNC therapy allows for better airway clearance and improved secretion management, making it a valuable adjunct in the treatment of respiratory conditions. However, the cost of

HFNC therapy and the lack of standardized protocols may limit its widespread adoption in some healthcare settings.

Conclusion:

In conclusion, high-flow nasal cannula therapy represents a significant advancement in non-invasive ventilation techniques, offering a safe and effective alternative to traditional oxygen therapy and invasive ventilation. The growing body of evidence supporting the use of HFNC therapy in various clinical settings underscores its potential to improve patient outcomes and reduce healthcare costs. Further research is needed to establish standardized protocols for HFNC therapy and to evaluate its long-term effects on respiratory function. As technology continues to evolve, advancements in NIV techniques such as HFNC therapy will play a crucial role in enhancing patient care and optimizing respiratory support.

REFERENCES:

1. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196.
2. Hernández G, Vaquero C, González P, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. JAMA. 2016;316(15):1565-1574.
3. Ni YN, Luo J, Yu H, et al. Can high-flow nasal cannula reduce the rate of reintubation in adult patients after extubation? Am J Emerg Med. 2017;35(11):1664-1669.
4. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest. 2015;148(1):253-261.
5. Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA. 2015;314(16):1711-1719.
6. Mauri T, Turrini C, Eronia N, et al. Physologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2015;191(10):1203-1208.
7. Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. Crit Care Med. 2015;43(3):574-583.
8. Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation: effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014;190(3):282-288.
9. Makdee O, Monsomboon A, Surabenjawong U, et al. High-flow nasal cannula versus conventional oxygen therapy in emergency department patients with cardiogenic pulmonary edema: a randomized controlled trial. Ann Emerg Med. 2017;70(4):465-472.e2.
10. Dannheimer N, Bernoulli L, Boggian K, et al. Establishment of high-flow nasal cannula oxygen therapy in Swiss emergency departments: a prospective observational multicenter study (OJECT). PloS one. 2017;12(8):e0189435.